BCL2 and diffuse large B-cell lymphoma: It has been reported that tirabrutinib in combination with idelalisib, entospletinib, and the BCL2 inhibitor ABT-199 synergistically increased apoptosis in primary CLL cells, a subset of DLBCL and MCL cell lines [10,18,19].